Why is Gilead extending the elvitegravir Phase III study?

Gilead is extending the study period to 96 weeks to gather more comprehensive safety and efficacy data, particularly from a direct, controlled, and blinded comparison of its investigational integrase inhibitor, elvitegravir, against raltegravir. This decision was made following a recommendation from the FDA.

Are there concerns about the safety or efficacy of elvitegravir?

No, Gilead explicitly stated in the filing that they have not been informed of any issues with the ongoing study that would cause them to halt or amend the study design. The extension is for gathering more data, not due to adverse findings.

Will this delay the approval of the 'Quad' combination therapy?

Gilead does not expect this planned change to impact the timelines for data availability from pivotal studies supporting the 'Quad' combination (Truvada®, elvitegravir, cobicistat) or the timelines for regulatory submissions, assuming positive outcomes from these studies.

What is the 'Quad' combination?

The 'Quad' refers to an investigational combination therapy developed by Gilead that includes Truvada® (emtricitabine and tenofovir disoproxil fumarate), elvitegravir, and cobicistat. It is designed for the treatment of HIV-1 infection.

GILD 8-K: Regulation FD

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K on January 10, 2011, to disclose an amendment to its ongoing Phase III clinical study for elvitegravir, an investigational integrase inhibitor for treatment-experienced HIV patients. Following a recommendation from the FDA, the company is extending the double-blinded study period from 48 weeks to up to 96 weeks. This extension aims to gather more comprehensive safety and efficacy data from a direct comparison between two integrase inhibitors, elvitegravir and raltegravir, within a controlled, blinded setting. Importantly, Gilead stated that there are no identified issues with the current study that would warrant halting or significantly altering its design. The company also anticipates that this change will not impact the expected timelines for data availability from ongoing pivotal studies of the investigational "Quad" combination (Truvada®, elvitegravir, and cobicistat), nor the anticipated timelines for regulatory submissions for the Quad, cobicistat, or elvitegravir, assuming positive study outcomes. The filing also includes standard forward-looking statement disclaimers, highlighting potential risks and uncertainties that could affect future results and commercialization.

Key Highlights

1Gilead is extending the double-blind study period for its investigational integrase inhibitor elvitegravir from 48 to 96 weeks, based on FDA recommendation.
2The study amendment aims to collect more extensive safety and efficacy data from a direct comparison of elvitegravir with raltegravir.
3Gilead has not encountered any issues that would lead to halting or altering the study design.
4The company expects no impact on the timelines for data from pivotal studies supporting the 'Quad' combination (Truvada®, elvitegravir, cobicistat).
5Regulatory submission timelines for the 'Quad', cobicistat, or elvitegravir are also not expected to be affected, pending positive study results.
6The filing includes standard forward-looking statements and risk disclosures related to drug development and regulatory approvals.

GILEAD SCIENCES, INC. 8-K Report, Regulation FD Disclosure (Jan 10, 2011)

Summary

Key Highlights

Frequently Asked Questions